Decreased levels of serum omentin-1 in patients with inflammatory bowel disease

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 118-122

  Yin, Jian ^a   Hou, Peng ^a   Wu, Zhiqiang ^a   Nie, Yanxiao ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adipokines; Inflammation; Inflammatory Bowel Diseases

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; OMENTIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; BLOOD EXAMINATION; BODY MASS; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SERUM OMENTIN 1 BLOOD LEVEL; ULCERATIVE COLITIS; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CROSS-SECTIONAL STUDY; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

ADIPOKINES; ADULT; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; LECTINS; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84920930390     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892081     Document Type: Article

References (23)

1. Trayhurn P: Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand, 2005; 184: 285–93
2. Kim A, Jung BH, Cadet P: A novel pathway by which the environmental toxin 4-Nonylphenol may promote an inflammatory response in inflammatory bowel disease. Med Sci Monit Basic Res, 2015; 21: 47–54
3. Schäffler A, Schölmerich J, Büchler C: Mechanisms of disease: adipocytokines and visceral adipose tissue – emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol, 2005; 2: 103–11
4. Ahualli J: The fat halo sign. Radiology, 2007; 242: 945–46
5. Peyrin-Biroulet L, Chamaillard M, Gonzalez F et al: Mesenteric fat in Crohn’s disease: a pathogenetic hallmark or an innocent bystander? Gut, 2007; 56: 577–83
6. Tan BK, Adya R, Randeva HS: Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med, 2010; 20: 143–48
7. de Souza Batista CM, Yang RZ, Lee MJ et al: Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007; 56: 1655–61
8. Mahde A, Shaker M, Al-Mashhadani Z: Study of Omentin1 and Other Adipokines and Hormones in PCOS Patients. Oman Med J, 2009; 24: 108–18
9. Yan P, Liu D, Long M et al: Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes, 2011; 119: 257–63
10. Zhong X, Zhang HY, Tan H et al: Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin, 2011; 32: 873–78
11. Kazama K, Usui T, Okada M et al: Omentin plays an anti-inflammatory role through inhibition of TNF-a-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol, 2012; 686: 116–23
12. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology, 1976; 70: 439–44
13. Irvine EJ, Feagan B, Rochon J et al: Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology, 1994; 106: 287–96
14. Wolf DC, Abraham BP, Afzali A et al: Community Perspectives: Combining Serology, Genetics, and Inflammation Markers for the Diagnosis of IBD and Differentiation Between CD and UC. Gastroenterol Hepatol (N Y), 2012; 8: 1–16
15. Weigert J, Obermeier F, Neumeier M et al: Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis, 2010; 16: 630–37
16. Karmiris K, Koutroubakis IE, Xidakis C et al: Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis, 2006; 12: 100–5
17. Desreumaux P, Ernst O, Geboes K et al: Inflammatory alterations in mesenteric adipose tissue in Crohn’s disease. Gastroenterology, 1999; 117: 73–81
18. Nanau RM, Neuman MG: Metabolome and inflammasome in inflammatory bowel disease. Transl Res, 2012; 160: 1–28
19. Yamawaki H, Kuramoto J, Kameshima S et al: Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun, 2011; 408: 339–43
20. Moreno-Navarrete JM, Ortega F, Castro A et al: Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring), 2011; 19: 1552–59
21. Liu R, Wang X, Bu P: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract, 2011; 93: 21–25
22. Pan HY, Guo L, Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract, 2010; 88: 29–33
23. Shibata R, Ouchi N, Kikuchi R et al: Circulating omentin is associated with coronary artery disease in men. Atherosclerosis, 2011; 219: 811–14